Abstract:BACKGROUND: China has a high prevalence of hepatitis B virus (HBV), but most chronic hepatitis B (CHB) patients do not receive standardized antiviral therapy. There are few relevant reports addressing the outcomes of the large number of CHB patients who do not receive antiviral therapy.AIM: To observe the outcomes of long-term follow-up of patients with CHB without antiviral treatment.METHODS: This study included 362 patients with CHB and 96 with hepatitis B cirrhosis without antiviral treatment and with only liver protection and anti-inflammatory treatment from 1993 to 1998. The median follow-up times were 10 and 7 years, respectively. A total of 203 CHB and 129 hepatitis B cirrhosis patients receiving antiviral therapy were selected as the control groups. The median follow-up times were 8 and 7 years, respectively. Kaplan-Meier curves were used to analyze the cumulative incidence of hepatocellular carcinoma (HCC), and the Cox regression model was used to analyze the risk factors for HCC.RESULTS: Among the patients in the non-antiviral group, 16.9% had spontaneous decreases in HBV DNA to undetectable levels, and 32.8% showed hepatitis B e antigen (HBeAg) seroconversion. In the antiviral group, 87.2% of patients had undetectable HBV DNA, and 52% showed HBeAg seroconversion. Among CHB and hepatitis B cirrhosis patients, the cumulative incidence rates of HCC were 14.9% and 53.1%, respectively, in the non-antiviral group and were 10.7% and 31.9%, respectively, in the antiviral group. There was no difference between the two groups regarding the CHB patients (P = 0.842), but there was a difference between the groups regarding the hepatitis B cirrhosis patients (P = 0.026). The cumulative incidence rates of HCC were 1.6% and 22.3% (P = 0.022) in the groups with and without spontaneous HBeAg seroconversion, respectively. The incidence rates of HCC among patients with and without spontaneous declines in HBV DNA to undetectable levels were 1.6% and 19.1%, respectively (P = 0.051). There was no difference in the cumulative incidence of HCC between the two groups regarding the patients with drug-resistant CHB (P = 0.119), but there was a significant difference between the two groups regarding the patients with cirrhosis (P = 0.004). The Cox regression model was used for regression of the corrected REACH-B score, which showed that alanine aminotransferase > 400 U/L, history of diabetes, and family history of liver cancer were risk factors for HCC among men aged > 40 years (P < 0.05). Multifactorial analysis showed that a family history of HCC among men was a risk factor for HCC.CONCLUSION: Antiviral therapy and non-antiviral therapy with liver protection and anti-inflammatory therapy can reduce the risk of HCC. Antiviral therapy may mask the spontaneous serological response of some patients during CHB. Therefore, the effect of early antiviral therapy on reducing the incidence of HCC cannot be overestimated.

Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy

Efficacy of different therapeutic modalities for patients with acute-on-chronic liver failure induced by hepatitis B

Effects of oral antiviral agents on long-term outcomes of treatment-naive patients with HBV-related decompensated cirrhosis: a retrospective cohort study]

Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status

Benefits of Long-Term Therapy with Nucleos(t)ide Analogues in Treatment-Naïve Patients with Chronic Hepatitis B

Long-term prognosis of patients with hepatitis B virus-related acute-on-chronic liver failure: a retrospective study

Real-world Study on Clinical Outcomes of Nucleos(t)ide Analogues Antiviral Therapy in Patients with Chronic Hepatitis B.

Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy

Role of viral factors and antiviral therapy in liver cirrhosis due to chronic hepatitis B

Survival analysis of HBV-related HCC patients with decompensated liver function and with/without antiviral therapy

Antiviral treatment and long-term clinical outcome of decompensated cirrhotic patients with hepatitis C virus infection

Effect of Antiviral Therapy on the Prognosis of Patients with Chronic Hepatitis B-related Cirrhosis

Efficacy of Antiviral Therapy with Nucleotide/nucleoside Analogs after Curative Treatment for Patients with Hepatitis B Virus-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis

Effects of Antiviral Effects of Agents and Prognosis of Chronic Hepatitis B

[Long-term prognosis and quality of life of survivors with hepatitis B virus-related acute-on-chronic liver failure]

Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy

Nucleoside Analogues Improve the Short-Term and Long-Term Prognosis of Patients with Hepatitis B Virus-Related Acute-On-Chronic Liver Failure

Analysis of the clinical characteristics and tr eatme nt of hepatitisB virus-related liver f a ilure

The Progress of Antiviral Therapy in Patients with HBV-related Liver Failure.

Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH)

Comparison of Interferon-α-based therapy and nucleos(t)ide analogs in preventing adverse outcomes in patients with chronic hepatitis B